Population modeling is transforming the way we leverage real-world data (RWD) to make informed decisions in healthcare. By simulating population dynamics and predicting the impact of interventions, these models help uncover actionable insights into treatment outcomes, healthcare utilization, and cost-effectiveness—offering a deeper understanding of how therapies perform in diverse, real-world settings. Population models are critical…
Our ability to generate data has, and continues to, undergo exponential growth over the course of our lives. As our data universe expands, we seek new and innovative ways to improve our everyday lives. One industry of focus includes healthcare, where researchers, pharmaceutical companies, payers, physicians, and more are constantly working to improve patient outcomes…
Artificial intelligence (AI) is rapidly transforming the healthcare industry, ushering in a new era of precision, efficiency, and personalized care. From enhancing diagnostics to optimizing treatment plans and streamlining administrative tasks, AI technologies are being integrated across various aspects of healthcare. With its ability to process vast amounts of data and deliver insights in real…
In today’s fast-paced healthcare landscape, the importance of gathering insights from diverse perspectives cannot be overstated. Healthcare advisory boards play a pivotal role in this process, serving as a bridge between industry stakeholders and the invaluable expertise of thought leaders, clinicians, and patient advocates. These boards provide a platform for discussion, collaboration, and strategic thinking,…
Health insurance in the US varies significantly in cost, coverage, care sites, provider networks, eligibility, and governing policies. To understand this complex landscape, it’s helpful to categorize insurance as either publicly or privately funded. Publicly funded plans include: Privately funded plans are also referred to as commercial plans. These can be: Employer-Sponsored Insurance Employer-sponsored insurance…
Gross to Net (GTN) is the income from all sales compared to revenue after discounts on the sales. When considering the gross to net for drugs, the calculation of the net revenue includes several components, courtesy of the complex outpatient drug distribution and reimbursement systems. The following are included in the calculation of net price: …
Health economics and outcomes research (HEOR) demand has grown alongside utilization of real-world data (RWD) in healthcare decision-making. Sectors influenced and impacted by use of HEOR evidence include pharmaceutical companies (manufacturers and distributors), healthcare institutions, payers, and government agencies. HEOR professionals hold vast knowledge in economic science and recent clinical studies and seek to improve…
Drug manufacturers offer voluntary discounts off list prices, known as drug rebates, but these are more complex than discounts for other healthcare products. This complexity arises from the various stakeholders involved and the types of rebates available. Formulary Placement Drug Rebate The primary recipients of rebates are commercial payers, including health insurance companies and pharmacy…
Transitional pass-through payments (TPTs) are a valuable tool for manufacturers looking to maximize market access and product adoption in the early stages of a product’s life cycle. By securing pass-through status, companies can accelerate market entry, support a strong pricing strategy, and gather essential real-world data to inform longer-term reimbursement strategies. This mechanism helps lay…
How Is the FDA Using PROs? The FDA has identified PROs1, also known as patient-generated health data (PGHD), as a focus area for regulatory science, given limitations with data collected in a controlled clinical setting, that patients are the experts in living with their condition, and therefore the FDA increasingly seeks to understand how patients…